Company
Headquarters: Beijing, China
Employees: 992
CN¥16.31 Billion
CNY as of Jan. 1, 2025
US$2.23 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Sinocelltech Group Limited, a biotech company, focuses on the development of technologies for the development and manufacturing of recombinant proteins, monoclonal antibodies, and vaccines in China. The company is based in Beijing, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥2.45 B |
| EBITDA | CN¥613.5 M |
| Gross Profit TTM | CN¥2.31 B |
| Profit Margin | -1.07% |
| Operating Margin | 32.95% |
| Quarterly Revenue Growth | 10.70% |
Sinocelltech Group Ltd has the following listings and related stock indices.
Stock: SSE: 688520 wb_incandescent